A humanized monoclonal sclerostin-neutralizing antibody (Scl-Ab) called romosozumab was approved in 2019 by the Food and Drug Administration (FDA) for treating osteoporosis in patients with a high risk of fracture, following years of clinical trials evaluating the pharmacology, efficacy, and safety [7]. This evidence concerns the gene SOST and osteoporosis.